Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BSEM | PRESS-RELEASE | bearish | 6/10 | BioStem Technologies announced a $40 million Committed Equity Facility (CEF) with Roth Principal Investments, allowing t | Sep 18, 2026 |
| CDT | PRESS-RELEASE | neutral | 4/10 | CDT Equity announced a partnership with QIMA Life Sciences to explore tapinarof (VTAMA®) combinations in autoimmune skin | Sep 18, 2026 |
| ETRA | PRESS-RELEASE | bullish | 7/10 | Electra Therapeutics priced its upsized IPO of 23,333,334 shares at $15.00 per share, raising approximately $350.0 milli | Sep 17, 2026 |
| BIIB | PRESS-RELEASE | bullish | 5/10 | Biogen published positive adolescent subgroup results from the Phase 3 VALIANT study of EMPAVELI in C3G and primary IC-M | Sep 17, 2026 |
| RARE | PRESS-RELEASE | bullish | 8/10 | Ultragenyx announced FDA approval of FAYUVI (UX-101) as the first-ever treatment for Sanfilippo syndrome Type A (MPS III | Sep 17, 2026 |
| ABT | PRESS-RELEASE | neutral | 2/10 | Abbott declared a quarterly common dividend of $0.63 per share, continuing its 411-quarter streak since 1924. The divide | Sep 17, 2026 |
| LSTA | PRESS-RELEASE | bullish | 7/10 | Lisata Therapeutics acquires Marea Therapeutics in a stock-for-stock transaction and concurrently raises $225 million in | Sep 17, 2026 |
| CELZ | PRESS-RELEASE | neutral | 2/10 | Creative Medical Technology Holdings filed a provisional patent application covering its Ultrasome cell-free regenerativ | Sep 17, 2026 |
| MIRA | PRESS-RELEASE | neutral | 3/10 | MIRA Pharmaceuticals announced submission of its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neur | Sep 17, 2026 |
| TELO | PRESS-RELEASE | neutral | 4/10 | Telomir Pharmaceuticals published peer-reviewed preclinical data showing Telomir-Zn improved visual function and reduced | Sep 17, 2026 |
| COAG | PRESS-RELEASE | neutral | 4/10 | Hemab Therapeutics dosed the first healthy volunteer in a Phase 1 trial of HMB-003, a novel peptide-based antifibrinolyt | Sep 17, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine's Chief of Global Impact presented insights from the company's clinical trial at Yale and Johns Hopki | Sep 17, 2026 |
| INDV | PRESS-RELEASE | neutral | 4/10 | Indivior declared a special cash dividend of $8.13 per share, contingent on the closing of its previously announced merg | Sep 17, 2026 |
| TLSA | PRESS-RELEASE | neutral | 4/10 | Tiziana Life Sciences signed a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on | Sep 17, 2026 |
| IPHA | PRESS-RELEASE | bullish | 6/10 | Innate Pharma's strategic partnership with Sobi for lacutamab is now effective after closing conditions were met, includ | Sep 16, 2026 |
| LGVN | PRESS-RELEASE | bearish | 7/10 | Longeveron announced that its Phase 2b ELPIS II trial of laromestrocel in HLHS failed to meet the primary endpoint (RVEF | Sep 16, 2026 |
| MAIA | PRESS-RELEASE | bullish | 7/10 | MAIA Biotechnology dosed the first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in third-line NS | Sep 16, 2026 |
| MYGN | PRESS-RELEASE | neutral | 3/10 | Myriad Genetics announced the promotion of Vishal Sikri to EVP-Commercial, replacing departing CCO Brian Donnelly. The c | Sep 16, 2026 |
| VIVS | PRESS-RELEASE | neutral | 5/10 | VivoSim Labs presented new clinical benchmark data at EUROTOX 2026 demonstrating its NAMkind™ 3D human liver and intesti | Sep 16, 2026 |
| ARTL | PRESS-RELEASE | bullish | 6/10 | Artelo Biosciences announced nonclinical results showing its oral dual cannabinoid agonist ART27.13 produced ~20% weight | Sep 16, 2026 |
| MAIA | PRESS-RELEASE | bullish | 5/10 | MAIA Biotechnology announced insider purchases totaling ~$325K by a board member and the CEO, signaling management confi | Sep 15, 2026 |
| BIVI | PRESS-RELEASE | mixed | 6/10 | BioVie announced topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID. The study failed to achieve stat | Sep 15, 2026 |
| BNTC | PRESS-RELEASE | neutral | 5/10 | Benitec Biopharma reported fiscal year 2026 results with a net loss of $45.5M ($0.98/share) vs $37.9M ($1.05/share) in F | Sep 14, 2026 |
| AGMB | PRESS-RELEASE | bullish | 6/10 | Agomab Therapeutics announced positive Phase 1 results for AGMB-447, a candidate for idiopathic pulmonary fibrosis (IPF) | Sep 14, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 4/10 | BriaCell announced its seventh consecutive positive DSMB recommendation for the pivotal Phase 3 Bria-ABC study of Bria-I | Sep 14, 2026 |
| KTTA | PRESS-RELEASE | neutral | 4/10 | Pasithea Therapeutics announced it will present initial clinical data from its ongoing Phase 1/1b trial of PAS-004 in ad | Sep 14, 2026 |
| TLX | PRESS-RELEASE | bullish | 8/10 | Telix Pharmaceuticals announced FDA approval of Pixclara® (floretyrosine F 18), the first FDA-approved FET-PET imaging d | Sep 14, 2026 |
| BNTX | PRESS-RELEASE | bullish | 7/10 | BioNTech and OncoC4 announced positive median overall survival (OS) data from stage 1 of the PRESERVE-003 Phase 3 trial | Sep 14, 2026 |
| CLLS | PRESS-RELEASE | neutral | 2/10 | Cellectis announced a conference call and webcast for September 14, 2026, to provide a business update. The press releas | Sep 11, 2026 |
| CRBP | PRESS-RELEASE | neutral | 5/10 | Corbus Pharmaceuticals announced a conference call for September 14 to discuss topline Phase 1b data for CRB-913, its no | Sep 11, 2026 |